Clozapine in community practice: A 3-year follow-up study in the Australian Capital Territory

Australian and New Zealand Journal of Psychiatry

Volumn 33, Issue 5, 1999, Pages 667-675

  Drew, Leslie R H ^a,b   Hodgson, Donna M ^b   Griffiths, Kathleen M ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CANBERRA HOSPITAL   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Clozapine; Community practice; Finance; Outcome; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DROWSINESS; ECONOMIC EVALUATION; EMPLOYMENT; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL BED UTILIZATION; HOSPITAL RUNNING COST; HUMAN; INCONTINENCE; MALE; ORAL DRUG ADMINISTRATION; PANCREATITIS; PRESCRIPTION; PSYCHOSIS; SALIVATION DISORDER; SCHIZOPHRENIA; SEDATION; SWEATING; TREATMENT OUTCOME; VERTIGO; VOMITING; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; COMMUNITY MENTAL HEALTH SERVICES; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032831978     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.1999.00631.x     Document Type: Article

References (21)

1. Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient. Journal of Clinical Psychiatry 1998; 59(Suppl. 1):13-19.
2. Morrison DP. Management of treatment refractory schizophrenia. British Journal of Psychiatry 1996; 169(Suppl. 31):15-20.
3. Aitchison KJ, Kerwin RVV. Cost-effectiveness of clozapine: a UK clinic-based study. British Journal of Psychiatry 1997; 171:125-130.
4. Herman M. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital. Australian and New Zealand Journal of Mental Health Nursing 1997; 337:809-815.
5. Rosenheck R, Cramer J, Xu W et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997; 337:809-815.
6. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomised trial. Psychopharmacology Bulletin 1996; 32:683-697.
7. Grace J, Bellus SB, Raulin ML et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Services 1996; 47:41-45.
8. Avnon M, Rabinowitz J. Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. British Journal of Psychiatry 1995; 167:760-764.
9. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. Journal of Clinical Psychiatry 1994; 55(9, Suppl.B): 161-165.
10. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 1990; 41:882-885.
11. Frankenburg FR, Zanarini MC, Cole JO, McElroy SL. Hospitalization rates among clozapine-treated patients: a prospective cost benefit analysis. Annals of Clinical Psychiatry 1992; 4:247-250.
12. Terkelsen KG, Grosser RC. Estimating clozapine's cost to the nation. Hospital and Community Psychiatry 1990; 41:863-869.
13. Rosenheck R, Chamey DS, Frisman LK, Cramer J. Clozapine's cost-effectiveness [letter]. American Journal of Psychiatry 1995; 152:152-153.
14. Breier A, Buchanan RW, Irish D, Carpenter WT. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hospital and Community Psychiatry 1993; 44:1145-1149.
15. Drew LRH, Hodgson D. Clozapine. Community use in the Australian Capital Territory. Australian Journal of Psychopharmacology 1997; 8:46.
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10:799-812.
17. Marinkovic D,Timotijevic I, Babinski T,Totic S, Paunovic VR. The side-effects of Clozapine: a four year follow-up study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994; 18:537-534.
18. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry 1996; 57(Suppl. 9):66-76.
19. Schiller M, Hargreaves WA. Clozapine's costs effectiveness [letter]. American Journal of Psychiatry 1995; 152:151-152.
20. Rosenheck R, Massari L, Frisman L. Who should receive high-cost mental health treatment and for how long? Schizophrenia Bulletin 1993; 19:843-852.
21. Schooler NR. New antipsychotic medications: strategies for evaluation and selected findings. Schizophrenia Research 1997; 27:249-259.